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Receptor tyrosine kinases (RTKs) are key transmembrane environmental
sensors that are capable of transmitting extracellular information into
phenotypic responses, including cell proliferation, survival and metabolism.
Advances in mass spectrometry (MS)-based phosphoproteomics have been
instrumental in providing the foundations of much of our current understanding
of RTK signalling networks and activation dynamics. Furthermore, new insights
relating to the deregulation of RTKs in disease, for instance receptor co-
activation and kinome reprogramming, have largely been identified using
phosphoproteomic-based strategies. This review outlines the current approaches
employed in phosphoproteomic workflows, including phosphopeptide enrich-
ment and MS data-acquisition methods. Here, recent advances in the application
of MS-based phosphoproteomics to bridge critical gaps in our knowledge of
RTK signalling are focused on. The current limitations of the technology are
discussed and emerging areas such as computational modelling, high-throughput
phosphoproteomic workflows and next-generation single-cell approaches to
further our understanding in new areas of RTK biology are highlighted.
1. Introduction
Since the discovery of the epidermal growth factor receptor
(EGFR) over 35 years ago, 90 genes in the human genome
have been identified to encode tyrosine kinases and, among
these, 58 belong to the receptor tyrosine kinase (RTK)
superfamily (Robinson et al., 2000). Classical features of RTKs
include an extracellular ligand-binding domain, a trans-
membrane region and a cytoplasmic domain which possesses
tyrosine kinase activity (Lemmon & Schlessinger, 2010).
Ligand binding induces receptor activation, typically via
receptor dimerization and autophosphorylation of tyrosine
residues on the intracellular tail. These phosphorylated resi-
dues function as docking sites to recruit cytoplasmic signalling
and adaptor proteins, providing a scaffold from which a vast
array of downstream networks can be initiated (Pawson,
2004). In this manner, RTKs act as environmental sensors that
are capable of converting extracellular information into
complex cellular responses.
Many RTKs orchestrate key cellular processes, including
cell survival, metabolism, proliferation and migration. As a
result, genetic aberrations which alter RTK expression,
localization or regulation can contribute to malignancies, and
are particularly prevalent in many cancers (Lahiry et al., 2010).
Given the critical role of RTKs in regulating cellular function,
there has been much effort in the last three decades to gain a
better understanding of RTK biology.
Technical developments in mass spectrometry (MS)-
based phosphoproteomics have provided powerful tools to
investigate important aspects of RTK biology. With advances
in phosphopeptide-enrichment strategies and metabolic and
chemical labelling techniques, large-scale quantitative phos-
phoproteomics has unravelled the complex and dynamic
nature of RTK signalling networks. In addition, MS-based
strategies to map RTK–protein interactions, their substrates
and their downstream pathways have led to new insights in
RTK biology, including the identification of new kinase-
substrate motifs and delineation of novel mechanisms of
kinase-inhibitor resistance (Huang, 2012). This technology has
been particularly useful in the context of cancer research,
where previously poorly understood phenomena such as
kinome reprogramming and RTK co-activation have now
been extensively characterized using mass spectrometry (Tan
et al., 2017).
Despite this progress, there are inherent limitations to MS-
based approaches. Owing to the complexity and low abun-
dance of the phosphoproteome, extensive sample-preparation
workflows and high-resolution mass spectrometers are
required to achieve substantial phosphosite coverage. This
often results in challenges such as a lack of data reproduci-
bility (Wolf-Yadlin et al., 2007), low-throughput analysis and
the need for relatively large amounts of input material
(Noujaim et al., 2016). In addition, in order to draw biologi-
cally meaningful conclusions from phosphoproteomic data,
computational strategies are necessary to effectively inter-
rogate RTK signalling networks and integrate this information
with other high-throughput profiling data such as genomics
and transcriptomics (Ren et al., 2011). This review outlines the
recent advances in applications of MS-based phospho-
proteomics in RTK biology. We briefly discuss contemporary
phosphopeptide-enrichment methods and data-acquisition
strategies and their applications to characterize important
aspects of RTK biology. We then offer a perspective on how
next-generation MS and computational strategies may over-
come the current limitations of phosphoproteomics to
advance our understanding of outstanding questions in RTK
research.
2. Mass spectrometry-based phosphoproteomics
Protein phosphorylation and its regulation through the
reciprocal actions of protein kinases and phosphatases play a
central role in many vital cellular processes. The phospho-
proteome is defined as the phosphorylated component of the
proteome in tissues or cells. The development of successful
phosphoproteomic methods is the result of technological and
sample-preparative improvements in three areas: (i) advances
in mass-spectrometer technology leading to high mass accu-
racy and rapid scan speeds, (ii) the development of selective
enrichment methods for phosphopeptides and (iii) improved
methods of phosphopeptide data acquisition and quantitation.
The central challenge in phosphoproteomics is the low
abundance of phosphorylated species within the proteome. A
minority of proteins are phosphorylated in the cell at any
given time and those proteins that are phosphorylated are
often present at low stoichiometry, frequently as low as 1%
(Wu et al., 2011). Thus, without some form of prior enrichment
and the use of highly sensitive mass spectrometers, few
phosphorylated species would reliably be detected in
direct liquid chromatography–mass spectrometry (LC-MS)
experiments. This section describes the most commonly used
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Figure 1
Overview of mass spectrometry-based phosphoproteomic workflows. Depending on the experimental design, there are a number of different strategies
which can be chosen to enrich specific compartments of the phosphoproteome. This is commonly followed by fractionation to reduce complexity and
increase coverage of complex cell lysates. Finally, the method of data acquisition will be influenced by the specific biological questions of interest when
interrogating proteomic data.
phosphopeptide-enrichment methodologies as well as current
data-acquisition strategies (Fig. 1).
2.1. Enrichment methodologies
Methods for phosphoprotein enrichment are broadly split
into chemical-based chromatography approaches, immune
affinity-purification methods and small-molecule binding
strategies (Fig. 2).
A number of chemical-based chromatography approaches
have been developed to enrich phosphoserine- and phos-
phothreonine-containing peptides while reducing nonspecific
binding, particularly by the more abundant acidic peptides.
Immobilized metal-affinity chromatography (IMAC) is an
established method in phosphoproteomics which uses metal
ions such as Fe3+, Zr4+ or Ga3+ that have been chelated to
suitable resins to selectively retain negatively charged
phosphopeptides (Ficarro et al., 2002). However, it should be
noted that such resins also bind tightly to acidic peptides, and
methods have been described to reduce this nonspecific
binding: for example, reducing the sample pH so that the
phosphate group but not glutamate or aspartate side chains
remain negatively charged or the methylesterification of the
side chains of acidic residues to reduce the binding of these
acidic peptides to the IMAC resin (Ficarro et al., 2002). Metal
oxide affinity chromatography (MOAC) using titanium
dioxide (TiO2) has also been extensively used for the affinity
isolation of phosphopeptides. The method makes use of the
affinity of oxygen in phosphoryl groups for the metal (Sano &
Nakamura, 2004). It has been shown that IMAC and TiO2
enrich different spectrums of phosphopeptides, and a
sequential combination of these two approaches has been
employed to gain an increase in the coverage of the phos-
phoproteome (Engholm-Keller et al., 2012).
Because of the large number of different phosphopeptides
present in cell and tissue lysates, additional fractionation is
often carried out to increase the depth of phosphoproteome
analysis. Methods orthogonal to conventional reverse-phase
chromatography are widely used. These include strong cation-
exchange chromatography (SCX) and hydrophilic interaction
chromatography (HILIC). SCX methods rely on the relatively
poor retention of negatively charged tryptic phosphopeptides
by the resin at low pH compared with the bulk of unmodified
tryptic peptides. The method was first applied to the large-
scale characterization of the HeLa cell nuclear phospho-
proteome to identify >2000 phosphosites on 967 proteins
(Beausoleil et al., 2004). HILIC is based on normal-phase
chromatography (except that it is compatible with mobile
phases containing water) using any of a variety of polar
bonded phases in which solutes are eluted in order of
increasing hydrophilicity. HILIC exploits the strong hydro-
philicity of phosphopeptides, and typically phosphopeptides
elute in the middle of the chromatogram, allowing substantial
fractionation and subsequent enrichment using either IMAC
or TiO2 (McNulty & Annan, 2008).
Immunoaffinity-based approaches are primarily employed
for the enrichment of tyrosine-phosphorylated peptides using
a number of commercially available pan-specific phospho-
tyrosine antibodies. Unlike phos-
phoserine and phosphothreonine
modifications, which represent 90
and 10% of the phosphopro-
teome, respectively, tyrosine
phosphorylation is a relatively
small fraction, accounting for less
than 0.1% of protein-phosphor-
ylation events in the cell (Hunter
& Sefton, 1980). Immunoprecipi-
tation using phosphotyrosine
antibodies has been used for the
enrichment of both tyrosine-
phosphorylated proteins and
peptides from cell lysate and
tissues (Rush et al., 2005). The
typical workflow for analysis of
tyrosine phosphorylation is as
follows. The cell lysate is
extracted prior to proteolysis and
the resulting digest is then
subjected to immunoprecipita-
tion with phosphotyrosine anti-
bodies. Further polishing of the
immunoprecipitated fraction can
be carried out using IMAC or
TiO2 to remove any nonspecific
peptide binding. This method has
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Figure 2
Advantages and disadvantages of enrichment and acquisition methods in phosphoproteomic workflows.
A comparison of the benefits and drawbacks of chemical, immunoaffinity and small-molecule-based
phosphoproteome enrichment and data-dependent (DDA), data-independent (DIA) and selective reactive
monitoring (SRM) acquisition methods, which must be considered when designing phosphoproteomic
experiments.
since been applied to examine dynamic phosphotyrosine
signalling in many RTK pathways (such as ErbB, c-MET,
PDGFR and FGFR) as well as the analysis of cell lines and
tissues. In the first large-scale analysis of phosphotyrosine
signalling in a panel of cell lines and tissues, Rikova and
coworkers analysed 41 non-small lung cell carcinoma cell lines
(NSCLCs) and over 150 tumours using this approach, and
identified a total of 4500 tyrosine-phosphorylation sites on
more than 2700 proteins (Rikova et al., 2007). This study
provided the first demonstration that multiple RTKs are
activated simultaneously in cancer cell lines and tissues, and
provided the foundation for future studies on the mechanisms
of RTK co-activation in cancer (Huang et al., 2010). The
combined use of chemical-based enrichment and phospho-
tyrosine immunoprecipitation has been shown to achieve an
extremely high depth of phosphoproteome coverage. For
instance, using a combination of SCX, TiO2 and phospho-
tyrosine antibody enrichment, Sharma and coworkers denti-
fied more than 38 000 phosphosites from 51 000 peptides in
HeLa cells over 17 d of MS acquisition time (Sharma et al.,
2014).
While phosphorylations on serine and threonine residues
are the predominant modifications present in the cellular
phosphoproteome, selective antibodies to phosphoserine or
phosphothreonine residues are not available owing to the
small size of the modified residue and consequent lower
antigenicity. However, a number of high-quality antibodies
have been raised against extended serine- and threonine-
phosphorylation motifs. Examples include the substrate motifs
for cyclin-dependent kinases (pS/pTP), the AKT kinase motif
(RxRxxpS/pT), and ATM and ATR (pS/pTQ), among others
(Joughin et al., 2009; Zhang et al., 2002; Matsuoka et al., 2007).
As with pan-specific phosphotyrosine antibodies, these kinase
substrate motif antibodies are used in immunoprecipitation
strategies to enrich phosphopeptides containing the motif of
interest. For example, ATM/ATR substrate antibodies have
been deployed to characterize the cellular response to DNA
damage in 293T cells subjected to ionizing radiation, which led
to the identification of more than 900 regulated phosphor-
ylation sites on >700 proteins (Matsuoka et al., 2007). Many of
these newly identified proteins are of unknown functions and
have subsequently been shown to be important for the DNA
damage-repair response (Huang & White, 2008; Matsuoka et
al., 2007).
Since many of the biologically significant phosphorylation
events occur in kinases, a number of affinity methods have
been developed to enable the enrichment and characterization
of the kinome in cells and tissues. By subjecting lysates to
immobilized panels of promiscuously binding kinase inhibi-
tors, these methods exploit the conserved nature of the ATP-
binding site present in all kinases to pull down a large fraction
of the kinases found in the cell. While these assays are not
strictly phosphopeptide-enrichment methods, they provide
complementary information about the protein abundance and
potentially activation states of different kinases in cells and
tissues. Bantscheff and coworkers used this approach to pull
down a large fraction of the total kinome with a panel of seven
immobilized kinase inhibitors chosen on the basis of their
broad and complementary specificity (Bantscheff et al., 2007).
Using these inhibitors (termed kinobeads) in pull-down
experiments, they identified 174 kinases from HeLa cell
extracts and a similar number from K562 cells. From a panel of
14 cell lines and tissues they were able to characterize a large
fraction (307 of 518) of the kinome. There is some controversy
as to whether these binding events represent the active
complement of the kinome. The assumption that such resins
predominantly bind kinases in their active form was chal-
lenged when Ruprecht and coworkers showed in a systematic
study that the immobilized kinase inhibitors showed no
preference for kinase activation (Ruprecht et al., 2015).
A more recent variant of the kinobead procedure uses a
combination of inhibitors with broad kinase selectivity as well
as clinically available tyrosine kinase inhibitors (TKIs). This
technique is known as multiplexed kinase inhibitor beads and
mass spectrometry (MIB/MS), and has been used to char-
acterize the reprogramming of the receptor tyrosine kinome
in response to targeted therapy in breast cancer (Stuhlmiller
et al., 2015; Duncan et al., 2012). Duncan and coworkers
employed this approach to demonstrate that the RTK profile
significantly alters in response to MEK inhibitor treatment in
the SUM159 triple-negative breast cancer cell line (Duncan et
al., 2012). They termed this phenomenon kinome repro-
gramming. This reprogramming induced resistance to MEK
inhibition, and the use of RTK inhibitors (sorafenib and
foretinib) to overcome kinome reprogramming restored
sensitivity to the MEK inhibitor AZD6244. These RTK
reprogramming effects appear to be a general cellular
response to targeted therapy, as subsequent studies have
shown that similar reprogramming events are responsible for
kinase-inhibitor resistance in ErbB2-positive breast cancer
cell lines and BET bromodomain-inhibitor resistance in
ovarian carcinoma cell lines (Stuhlmiller et al., 2015; Kurim-
chak et al., 2016). These studies highlight the power of affinity
pull-down experiments in identifying novel RTK-based stra-
tegies to overcome targeted therapy resistance in multiple
cancer types.
Finally, a chemical genetic approach which employs kinases
engineered with the ability to use analogues of adenosine
50-triphosphate (ATP), so-called analogue-sensitive (AS)
kinases, has been employed to isolate kinase-specific
substrates for downstream phosphoproteomic analysis. An
analogue-sensitive ERK2 (AS-ERK2) was used by Carlson
and White to identify ERK substrates by tagging them with
-thiol-phosphate ATP analogues in NIH 3T3-L1 fibroblasts
(Carlson & White, 2012). Following the capture of thiophos-
phorylated substrate residues, coupled with IMAC to reduce
nonphosphorylated background peptides, Carlson and White
were able to establish 98 sites on 80 proteins phosphorylated
by AS-ERK2, including a novel and functionally relevant
phosphorylation of the E26 (ETS) domain-containing protein
ETV3. This study exemplifies the use of AS kinases for
focused kinase-substrate studies; however, caution must be
taken to validate these findings in order to rule out the
potential false positives which might arise by the nonspecific
topical reviews
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utilization of ATP analogues by endogenous kinases within
the cell.
2.2. Data-acquisition methodologies
The data-acquisition methodology used to acquire phos-
phoproteomic data is a critical consideration that influences
the type of data generated in MS experiments, and the choice
of which method to use is largely dependent on the nature of
the proteomic application of interest (Fig. 2). For many years,
MS-based proteomics have been carried out using data-
dependent acquisition (DDA; Fig. 3a). In this approach,
peptides eluting from the liquid-chromatography (LC) column
become ionized in the mass spectrometer (Aebersold &
Mann, 2016). The mass/charge (m/z) ratio is determined in the
first stage of the instrument (the MS1 stage) and typically the
10–20 most abundant precursors are selected for fragmenta-
tion in the second MS2 stage. Conventional LC conditions
mean that the tens of thousands of peptides present in a
complex sample will elute over the course of a 1–4 h gradient.
In this approach, the selection of peptide precursor ions tends
to be a stochastic process (albeit biased to the more abundant
peptide species) such that the overlap between two technical
replicates (in peptides identified) is routinely less than 70%
(Wolf-Yadlin et al., 2007). This stochastic process means that
many peptides in complex mixtures will go undetected and
peptides will not be reproducibly detected. The main advan-
tage of this method is that it is unbiased, facilitating the
discovery of new phosphorylation events in a single LC-MS
run. As mass-spectrometer technology improves and scan
speeds and cycle times become shorter and detectors more
sensitive, it is anticipated that some of these limitations of
reproducibility will gradually diminish.
A second strategy for data acquisition is targeted proteo-
mics based on selective reaction monitoring (SRM; Fig. 3b);
which utilizes the knowledge gained from DDA experiments
to generate in silico peptide libraries that enable the specific
targeting and quantification of several hundred phosphoryl-
ated peptides simultaneously in a single LC-MS experiment.
These SRM experiments are typically carried out on a triple-
quadrupole mass spectrometer and specific precursor ions
(corresponding to peptide precursors of interest previously
identified in DDA discovery experiments) are selected in the
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Figure 3
Schematic comparison of mass-spectrometric data-acquisition methodologies. (a) DDA: precursors identified in the first MS1 stage are selected for MS2
fragmentation on the basis of abundance. Software matches the masses to the database (in silico ‘trypsinized’ proteins). This is the standard discovery
mode allowing the identification of novel proteins and phosphorylation sites. (b) SRM: precursors chosen on basis of prior discovery experiments in the
MS1 stage; following fragmentation, signature MS2 peaks are also selected. The integration of these transitions can be used for quantitation. (c) DIA: no
precursor selection in the MS1 stage; instead, all ions in wide overlapping mass windows (typically 25 mass units) over the whole mass range (from 400 to
1200 m/z) are fragmented. Using spectral libraries obtained in DDA experiments, MS2 spectra corresponding to specific peptides can be extracted.
first quadrupole. These selected precursors pass into the
second quadrupole, where they are fragmented and all
precursors outside of the narrow mass-selection window are
discarded. In the final stage of the mass spectrometer, selected
fragments of interest are isolated and measured in the final
quadrupole (Carr et al., 2014). Because this strategy employs
an a priori-defined in silico library of peptides, the lack of
reproducibility associated with stochastic sampling in DDA is
avoided, leading to a close to 90% overlap between peptides
identified in technical replicates. One of the early applications
of this strategy to RTK signalling was performed by Wolf-
Yadlin and coworkers, who utilized SRM to quantify tyrosine
signalling downstream of EGF stimulation in human
mammary epithelial cells (Wolf-Yadlin et al., 2007). Here, the
authors ‘tracked’ 222 tyrosine-phosphorylation sites and
showed that while typical DDA strategies led to poor repro-
ducibility of 34% across four replicates, SRM was superior in
its ability to reproducibly quantify 88% of all the
phosphorylation sites monitored. While SRM generates highly
reproducible data sets, unlike DDA-based approaches, the
development of high-quality assays requires significant opti-
mization and lead time (Carr et al., 2014). Furthermore, these
assays have a limited depth of phosphoproteome coverage,
often restricted to several hundred phosphorylation sites
(Kennedy et al., 2016). Finally, owing to their reliance on a
priori in silico libraries, SRM approaches do not allow the
discovery of new proteins and post-translational modifications
that are commonly associated with DDA.
An alternative strategy to DDA and SRM is data-
independent acquisition (DIA), which is also known as
sequential window acquisition of all theoretical fragment-ion
spectra (SWATH; Fig. 3c). In this approach, all peptide
precursor ions present in wide overlapping (typically 20 Da)
windows across the whole mass range are fragmented (Hu et
al., 2016), generating all possible precursor fragment-ion (MS/
MS) spectra. The major challenge with DIA is the require-
ment to extract the information for a given precursor from the
resulting complex MS2 data, which will contain thousands of
fragment ions. As a result, this data-acquisition methodology
relies heavily on bioinformatics tools to deconvolute complex
mass spectra; for instance, using data from prior experiments
in DDA mode to generate spectral libraries which can be used
in the interrogation of DIA data (Ro¨st et al., 2014). The main
advantage of this method is that, unlike DDA approaches,
the DIA data can be retrospectively interrogated for
proteins of interest. Employing DIA, Parker and coworkers
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Figure 4
Advances in understanding RTK biology using mass spectrometry-based phosphoproteomic studies. A timeline of key studies which illustrate the
development of MS-based phosphoproteomics and their application in advancing our knowledge of RTK biology. The timeline depicts the pioneering
phosphoproteomic studies performed a decade ago in addition to highlighting novel and innovative research from the last five years.
demonstrated the utility of this approach to quantify the
phosphorylation of multiple components of the insulin
receptor signalling cascade and were able to demonstrate that
AKT2-dependent phosphorylation of GAB2 inhibited EGF
signalling and promoted insulin signalling in a 14-3-3 binding
manner (Parker et al., 2015). DIA methodology is still very
much in its infancy and it is anticipated that as the technology
and software become more widespread in use, this approach
will be deployed for more RTK studies in the near future
3. Mass spectrometry unveils new RTK biology
In the last decade, the use of MS-based phosphoproteomics
has been integral to RTK research (Fig. 4). This includes the
characterization of the mechanisms of action of many RTKs
that are deregulated in cancer and other diseases such as
diabetes, studies of resistance mechanisms to kinase inhibitor
therapy and modelling the kinetics of RTK signalling (Huang,
2012; Tan et al., 2017). In this section, we highlight the most
recent applications of MS-based phosphoproteomics to
unravel new aspects of RTK biology.
3.1. New insights in EGFR phosphorylation dynamics and
downstream signalling
EGFR is the prototypical member of the RTK superfamily
and has been the subject of multiple phosphoproteomic
studies over the past decade (Mertins et al., 2012; Olsen et al.,
2006; Zhang et al., 2005). By quantifying the dynamics asso-
ciated with EGFR activation and its downstream signalling in
a range of cell lines, these studies have detailed the canonical
EGFR signalling networks, which has led to important appli-
cations in human health and disease. Despite the wealth of
prior knowledge associated with this well studied receptor,
there are several outstanding fundamental questions that
remain unanswered. For instance, all studies to date have
focused on signalling that occurs on the minutes to hours
timescale after ligand stimulation, and the nature of the
immediate early signalling networks remains unknown.
Furthermore, it has been a challenge to directly compare the
phosphorylation levels across different sites on the EGFR
protein since all published studies have thus far relied on
relative quantification to a reference sample/condition. Given
that site-specific receptor phosphorylation has a direct impact
on adaptor recruitment and propagation of downstream
signalling, the ability to map absolute levels of receptor
phosphorylation has profound implications for our under-
standing of EGFR signalling.
Recent studies have started to shed light on these important
questions. For instance, Reddy and coworkers focused their
efforts on mapping the phosphotyrosine signalling events at
high temporal resolution within a timeframe of seconds
(Reddy et al., 2016). Using the MCF10A cell line as a model
system, they employed phosphoproteomics to characterize the
signalling profiles for the first 80 s after EGF stimulation at
10 s intervals over eight different growth-factor concentra-
tions. They quantified several hundred tyrosine-phosphoryl-
ation sites and were able to show that EGFR was capable of
initiating downstream signalling almost immediately after
ligand activation. They also identified very early phosphor-
ylation changes on proteins not previously known to be in the
EGFR pathway, such as the cytoskeletal components cortactin,
plakophilin and tensin. By integrating these phosphorylation
data with localization measurements using proximity ligation
assays, the authors demonstrated that the binding of the
receptor to adaptor proteins such as SHC and GAB1 occurs
on similar timescales as phosphorylation, suggesting that
adaptor recruitment to the receptor may be the primary rate-
limiting step in regulating early phosphorylation events.
To tackle the issue of absolute phosphorylation measure-
ments in EGFR, Curran and coworkers developed a method
which combined chemical labelling with isotopically labelled
synthetic peptides to generate internal standard curves for
phosphopeptides in the EGFR signalling network (Curran et
al., 2015). They called this approach the multiplex method
for absolute quantitation of peptides and post-translational
modifications (MARQUIS). By analysing MCF10 cells
stimulated with EGF, the authors demonstrated for the first
time that the Tyr1148 site was phosphorylated at a fivefold
higher level than Tyr1173, Tyr1068 or Tyr1045. This was an
interesting finding, as Tyr1173 rather than Tyr1148 is classi-
cally considered to be the dominant autophosphorylation site
on EGFR (Voldborg et al., 1997). By comparing the signalling
dynamics across three distinct EGF family ligands (EGF,
TGF and amphiregulin), the authors determined that the
comparative phosphorylation pattern of different receptor
sites remained quantitatively consistent regardless of the
ligand used. This finding suggests that the biological responses
associated with different EGF ligands may be the result of
quantitative differences in receptor phosphorylation (changes
in absolute levels of phosphorylation at different sites) rather
than qualitative differences (the activation of different phos-
phorylation sites on the receptor by different ligands). By
utilizing these new approaches to analyse EGFR signalling,
these two studies have challenged the established dogma in
the field, generating new insights into EGFR biology for
further investigation.
3.2. Defining the canonical signalling in poorly characterized
RTKs
Out of the 58 RTKs in the human genome, there is still a
large fraction of receptors that remain poorly characterized
and for which the canonical signalling pathways are unknown
(Lemmon & Schlessinger, 2010). Several recent studies have
highlighted the utility of phosphoproteomics to map, for the
first time, the downstream signalling pathways in a subset of
these poorly characterized receptors, including DDR2, MuSK
and ErbB4 (Iwai et al., 2013; Durnberger et al., 2014;
Wandinger et al., 2016).
The discoidin domain receptors (DDRs) are a class of
RTKs, comprising DDR1 and DDR2, that are activated by
binding to collagen rather than growth-factor ligands (Iwai et
al., 2014). Upon ligand stimulation, these receptors display a
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unique delayed activation profile that results in the initiation
of phosphorylation only hours after ligand engagement.
Furthermore, unlike other RTKs, DDR signalling is sustained
over several days with no apparent negative regulatory
mechanisms. The receptor-phosphorylation sites and signal-
ling pathways activated by the DDRs are poorly annotated,
making it challenging to define the mechanistic basis of the
cellular phenotypes associated with this class of receptors.
Combining IMAC enrichment and phosphotyrosine immuno-
precipitation, our laboratory has performed a global phos-
phoproteomic analysis to characterize the signalling networks
activated by DDR2 over seven time points (0–24 h) after
collagen stimulation (Iwai et al., 2013). Using multiple clus-
tering strategies, a subset of tyrosine-phosphorylated proteins
was identified as candidate substrates of DDR2 activation,
including the SHP2 protein tyrosine phosphatase. Having
determined the key receptor-phosphorylation sites and
signalling pathways activated by DDR2, we further demon-
strated that the mechanism of action for kinase-domain
mutations of DDR2 in lung cancer was kinase inactivation and
the inability to initiate receptor phosphorylation and down-
stream signalling. This resulted in a loss of receptor function,
alleviating the growth-suppressive properties of DDR2, and
an increase in colony formation by these cancer-associated
mutants (Payne & Huang, 2014).
The muscle-specific kinase (MuSK) is required for the
formation of the neuromuscular synapse (Kim et al., 2008).
It is activated by the heparin sulfate proteoglycan agrin in
complex with the Lrp4 receptor (Kim et al., 2008). Durnberger
and coworkers used myotube cells as a model system to study
the global phosphorylation effects of MuSK activation by
agrin over four time points (0–240 min; Durnberger et al.,
2014). Employing a combination of TiO2 enrichment and SCX
fractionation, the authors quantified >10 000 phosphopeptides,
of which 203 phosphopeptides on 152 proteins were signifi-
cantly regulated by agrin stimulation of MuSK. By subjecting
these phosphopeptides to K-means clustering, they identified
both early-response (15 min) and late-response (1 and 4 h)
clusters. Pathway-enrichment analysis of early signalling
events identified a strong enrichment of actin cytoskeletal
proteins, which included paxillin, talin and vinculin, among
others. These proteins are known to play a key role in the
regulation of the cytoskeleton, which is consistent with the
knowledge that neuromuscular synapse formation is accom-
panied by significant cytoskeletal reorganization. This study
represents the first analysis of MuSK RTK signalling and
presents a useful paradigm for further functional analysis of
the relationship between downstream effector signalling and
neuromuscular synapse cytoskeletal reorganization.
The EGFR or ErbB receptor class is composed of four
family members: EGFR, ErbB2, ErbB3 and ErbB4 (Citri &
Yarden, 2006). ErbB4 remains the most poorly characterized
member of this class of receptors. ErbB4 is capable of forming
homodimers and heterodimers, and it has been shown that the
neuregulin-1 (NRG1) ligand promotes the homodimerization
of ErbB4 as well as the heterodimerization of ErbB4 with
ErbB3 (Citri & Yarden, 2006). However, the downstream
signalling events activated by ErbB4 homodimers and ErbB3/
ErbB4 heterodimers are unknown. In a recent study,
Wandinger and coworkers ectopically expressed ErbB4 alone
or ErbB3 and ErbB4 in the murine Ba/F3 model cell-line
system and analysed the phosphorylation signals upon NRG1
stimulation (Wandinger et al., 2016). Interestingly, the co-
expression of ErbB3 in combination with ErbB4 promoted
enhanced proliferation compared with cells expressing ErbB4
alone, suggesting that the heterodimer induces more potent
cellular signalling. Using MS-based phosphoproteomics, the
authors identified >9600 phosphosites, of which 492 were
significantly altered in ErbB3/ErbB4-expressing Ba/F3 cells.
Kinase substrate-motif analysis of these phosphosites found
that the AKT substrate motif was enriched in response to
NRG1 stimulation. Comparing the ErbB3/ErbB4 and ErbB4-
specific phosphorylation data identified 54 phosphosites that
were distinct between the two cell lines. Importantly, all of
these sites were found to be more highly phosphorylated upon
the co-expression of ErbB3, suggesting that ErbB3 serves an
important function as a broad amplifier of ErbB4 signalling.
Taken together, these three studies highlight the utility of
phosphoproteomics to elucidate the signalling networks of
poorly characterized RTKs. There remain a large number of
RTKs for which the canonical signalling networks are
unknown, including INSRR, MER, LTK and the majority of
the Eph receptors, among others, and further efforts to curate
the downstream phosphorylation events activated by these
receptors will be necessary.
3.3. Interplay of EGFR post-translational modification events
Phosphorylation is one of many post-translational modifi-
cations (PTMs) that are important for signal transduction,
and thus phosphoproteomics data only present one facet of
complex cellular signalling systems. In addition to
phosphorylation, other prominent protein-modification events
include glycosylation, ubiquitination and acetylation. Several
MS-based approaches have been developed to integrate
phosphorylation analysis with other PTMs. Mertins and
coworkers proposed a strategy of serial enrichments of
different post-translational modifications (SEPTM), which
uses MS to simultaneously study protein phosphorylation,
ubiquitination and acetylation. The technique requires a large
amount of starting material and rigorous sample fractionation
and serial enrichment, using IMAC to enrich for phospho-
peptides and antibodies to pull down ubiquitinated and
acetylated peptides, leading to a deep interrogation of
multiple PTMs from a single biological sample (Mertins et al.,
2013). Using this approach, they identified 20 000 phospho-
sites, 15 000 ubiquitination sites and 3000 acetylation sites in a
single experiment. By correlating changes in protein
abundance and PTMs in Jurkat cells treated with bortezomib,
a proteasome inhibitor, the authors were able to isolate
six functional major nodes which were co-regulated and
associated with key cellular process including cell cycle,
transcription and proteasomal regulation.
More recently, Francavilla and coworkers expanded on this
strategy and applied it in the study of EGFR signalling
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(Francavilla et al., 2016). The authors utilized mass spectro-
metry to analyse the ubiquitinome, phosphoproteome, inter-
actome and proteome alterations in HeLa cells stimulated
with the EGFR ligands EGF and TGF. They termed this
strategy an integrated multi-layered proteomics approach
(IMPA). EGF and TGF elicit distinct biological phenotypes,
signalling and receptor trafficking responses downstream of
EGFR activation (Roepstorff et al., 2009). For instance, EGF
promotes EGFR degradation after internalization, while
TGF induces the recycling of active receptor. The authors
subjected cells to stimulation with either of the two ligands for
1, 8, 40, 90 min or 72 h and performed multi-stage enrichment
of ubiquitinated peptides by immunoprecipitation and phos-
phorylation by immunoprecipitation and TiO2 enrichment.
They identified >5500 phosphosites on 1949 proteins, of which
23% were regulated by ligand addition, and 1311 ubiquitin-
ated peptides on 782 proteins, of which 17% were ligand-
regulated. Furthermore, they conducted receptor-interaction
analysis by co-immunoprecipitation of endogenous EGFR
and also quantified alterations in the proteome at 72 h after
stimulation. Using these disparate data sets, they focused on
67 proteins that were regulated in more than one data set.
They showed that EGF and TGF differed in their temporal
regulation of global ubiquitination to a greater extent than
global phosphorylation levels, with TGF promoting
enhanced cellular ubiquitination. Furthermore, there appears
to be crosstalk in the regulation of both the cellular ubiqui-
tination and phosphorylation machinery, where the authors
demonstrated that ubiquitin E3 ligases and deubiquitinating
enzymes are phosphorylated, while kinases and phosphatases
are ubiquitinated. The presence of multiple PTM data sets also
facilitates the assessment of PTM crosstalk on the 260 proteins
that were both phosphorylated and ubiquitinated. Of these
proteins, only 25 were regulated at the level of both PTMs,
with EGF stimulating phosphorylation at early time points
(within 8 min) and TGF activating both sustained phos-
phorylation and prolonged ubiquitination; highlighting the
opposite PTM profiles in response to the two EGFR ligands.
These findings shed light on the complex interplay and
crosstalk between different PTMs in signalling networks and
suggest that future experiments will need to consider the
effects of both phosphorylation and ubiquitination in the
regulation of RTK signalling. On a more general note, while
increasing the number of PTM ‘layers’ analysed by MS will
present challenges in big-data analysis and interpretation,
understanding the roles of multiple PTMs and their crosstalk
in signalling networks will be necessary in order to gain a more
holistic understanding of biological processes regulated by
RTKs.
4. Future perspectives
Our current understanding of the signalling dynamics in many
RTKs has relied on the ability to perform quantitative, large-
scale global phosphorylation analysis. However, there are still
a number of important questions which remain unanswered.
Emerging technologies which improve upon current MS-
based approaches will provide new opportunities to investi-
gate burgeoning areas of RTK research.
4.1. Computational modelling of phosphoproteomic data
There is a need to develop better computational methods
to interrogate phosphoproteomic data. A major challenge in
dealing with large phosphoproteomic data sets is finding an
effective way to distil key interactions to better understand
RTK signalling dynamics. Several research groups have begun
to apply innovative computational strategies to model
RTK networks and integrate phosphoproteomics with other
large data sets. Terfve and coworkers developed a method
named phosphorylation networks for mass spectrometry
(PHONEMeS) to investigate drug perturbations of cell
signalling in the context of known interactions (Terfve et al.,
2015). The authors constructed signalling networks using logic
model building and training to integrate known or predicted
kinase–phosphatase and kinase–substrate interactions from
multiple data sources with newly acquired phosphoproteomic
data. This type of analysis is capable of framing phospho-
proteomic data onto a network of known protein relation-
ships, but emphasizes biologically meaningful signalling routes
instead of focusing on key interaction nodes. Analysing
phosphoproteomic data using this approach can provide new
insights that might otherwise be missed by using the analysis
of protein–protein interaction databases such as STRING
(Szklarczyk et al., 2015).
Another group has developed a computational method
designed to deal with a common problem in MS-based phos-
phoproteomic data sets, which is handling false-negative
results (Grimes et al., 2013). Missing values in data sets often
result as a byproduct of sample loss during preparation and
enrichment as well as stochastic sampling in the DDA mode.
Instead of imputing missing values, Grimes and coworkers
calculated statistical relationships between the observed values
using protein–protein interaction data and pattern recognition
to create protein network clusters. In a follow-up study, this
technique was applied to phosphoproteomic data in neuro-
blastoma cell lines, where endosomal and detergent-resistant
membrane cell fractions were isolated (Palacios-Moreno et al.,
2015). By examining interactions between co-clustering
groups of proteins, the authors were able to elucidate an
intricate crosstalk pattern between distinct groups of tyrosine
kinases. In addition, this study addressed a poorly understood
area of RTK biology, the regulation of RTK signalling
networks via intracellular spatial compartmentalization.
Perturbation of neuroblastoma cells with TKIs or stimulation
with growth factors revealed distinct enrichment of specific
RTKs to different intracellular compartments. Although it is
still too early to draw general conclusions about how RTK
spatial distribution regulates signalling networks, it is likely
that future in-depth studies using these new computational
approaches will generate new insights that will resolve the
regulation of RTK signalling dynamics at this level of spatial
detail.
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4.2. Increasing the throughput of phosphoproteomics
experiments
In the context of cancer biology, there is an urgent need to
develop rapid and comprehensive profiling of RTK signalling
in large-scale panels of cell lines and tumours. Unlike other
contemporary profiling approaches such as DNA and RNA
sequencing, proteomics lacks the throughput required to
generate the high-density phosphoprofiles that are necessary
for understanding and targeting disease. Identifying RTK
signalling profiles on a patient-by-patient basis is required to
contribute to ongoing efforts to develop personalized medi-
cine in the form of tailored treatment strategies. To address
this challenge, Humphrey and coworkers recently developed
a high-throughput, scalable platform for phosphoproteomics
termed EasyPhos (Humphrey et al., 2015). This workflow was
optimized to allow proteome digestion and phosphopeptide
enrichment in a 96-well format, facilitating the processing of
multiple samples in parallel. Using this method, the authors
were able to reach a depth of >10 000 phosphosites in mouse
liver, kidney and brain tissue samples over the course of 1.5 d
of mass-spectrometry acquisition. Such high-throughput
phosphoproteomics techniques will speed up the translation of
routine and affordable tumour phosphoprofiling in a clinical
setting (Noujaim et al., 2016). In addition, the study demon-
strates the suitability of this platform for performing large-
scale RTK signalling experiments. The authors were able to
quantify signalling events downstream of the insulin receptor
in mouse liver tissue across 11 stimulation time points with 6–
10 biological replicates per time point. The ability to perform
phosphoproteomics on this scale will facilitate experiments
designed to robustly interrogate temporal RTK signalling
dynamics with greater detail and precision.
4.3. Resolving single-cell RTK signalling and population
heterogeneity
One drawback of current phosphoproteomics strategies is
that these measurements routinely require large amounts of
starting material, and as a result are often carried out with
high cell numbers or entire tissue sections. This limits the
phosphorylation information generated to population-level
measurements lacking resolution at the single-cell level.
However, it is now evident that cell lines and tumours display
significant heterogeneity in RTK expression and activation
and are composed of several distinct subpopulations: a
phenomenon first documented in glioblastoma (Snuderl et al.,
2011) and more recently described in colorectal tumour
specimens by the Clinical Proteomic Tumour Analysis
Consortium (CPTAC; Gajadhar et al., 2015).
Recent advances in mass cytometry increases the capability
to collect measurements from tissue subpopulations with fine
detail, even down to the single-cell level. Mass cytometry
derives from the principles of flow cytometry, but instead of
using fluorophore-tagged antibodies for staining, antibodies
are conjugated with metal-isotope tags (Bendall et al., 2011).
Detection of these mass-tagged antibodies is achieved through
cytometry by time of flight (CyTOF). TOFmass spectrometers
are able to distinguish ‘nonbiological’ rare-earth metal
isotopes, creating the potential to carry out multiplexed
measurement of up to 100 analytes from a single sample: a
number which is expected to increase as the technology
develops (Angelo et al., 2014). CyTOF can be combined with
high-resolution laser ablation of tissue samples prepared in
a similar manner to immunohistochemistry (IHC) staining.
Using this approach, Giesen and coworkers were able to
detect 32 proteins and phosphorylation sites simultaneously
on breast cancer tissue, with a resolution of 1 mm (Giesen et
al., 2014). A similar approach called multiplexed ion-beam
imaging (MIBI) has been used to achieve an even greater
resolution of 50 nm (Angelo et al., 2014). The images produced
look similar to traditional IHC staining and use software
which overlays quantitative mass-spectrometry data onto their
spatial location in the tissue. Given the exciting developments
in the field of mass cytometry, this technology is primed to be a
powerful tool to investigate the RTK signalling heterogeneity
in tumour specimens as well as provide single-cell resolution
to RTK signalling analysis in cell-culture experiments.
5. Concluding remarks
Over the past decade, advances in sample preparation, phos-
phopeptide enrichment, data-acquisition methods and new
MS instrumentation have increased our knowledge of the
mechanisms of RTK regulation and signalling. Despite this
progress, there are a significant number of areas in RTK
biology which have yet to be fully explored. The function and
signalling of a large number of RTK family members is still
poorly characterized. There is much to be learned about the
temporal signalling kinetics of many of these receptors and
the degree of co-activation and crosstalk between individual
RTKs. There is also a need to investigate RTK spatial distri-
bution, both in terms of heterogeneous receptor expression
and activation in tissue, and intracellular RTK compartmen-
talization. State-of-the-art MS approaches such as those
discussed in this review directly address some of the current
gaps in our knowledge. Coupled with effective computational
modelling and integration of disparate data sources, including
proteomic, transcriptomic and epigenomic information, with
techniques such as the prize-collecting Steiner forest and tree
approach (Huang et al., 2013; Tuncbag et al., 2013), these new
strategies will be critical in ushering in a new era of RTK
research. The use of these technologies over the next decade
will undoubtedly yield exciting new insights into RTK
signalling and reveal the impact of deregulating these critical
networks in diseases such as cancer.
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